Skip to content
NASDAQ · PHARMACEUTICAL PREPARATIONS · LARGE CAP

Spyre Therapeutics, Inc. SYRE

12 fiscal years on record · USD · FY2025 reported · SEC filings only
$0
$-155.2M

Slide the table for earlier years · "·" marks a figure not available in our data for that year.

Growth

USD 0.00
Revenue, FY2025 · full 12-year series below
Revenue $M Net income $M
FY2025 · Revenue 0.0 · Net income -155.2
-150M-300M
20142017202020232025
Compound annual growth
3 yrs
5 yrs
10 yrs
15 yrs

Compound annual rates per period — left blank where that exact year isn't on file, the series crosses a loss, or (per-share rows) a split falls inside the window.

Profitability

·
Operating margin Net margin
FY2023 · Operating -27348.0% · Net ·
-10000%-20000%
201420192025
ROE
FY2025 · ROE -25.2%
-100%-200%
201420192025
Three returns, three denominators.

Each USD of equity lost 25 cents this year.

Cash & shareholders

·
returned in FY2025 · dividends + net buybacks
Free cash flow $M
FY2024 · FCF -157.4
-100M-200M
201420192025

Total assetsUSD 777.8M
EquityUSD 715.2M
CashUSD 85.7M
Current ratio13.25×

Equity funds 92% of total assets.

The 12-year record

12 fiscal years
Every figure from documents filed with the SEC · USD

EPS, diluted, dividend per share and shares outstanding are shown without shading, and a vertical line marks the year the share count changed — the series crosses a large, unexplained change in share count, so the years on either side are not on a comparable scale.

row low → row highnegative—not applicable◌not available in our data
SYRE, 12-year financial record
Metric 202520242023202220212020201920182017201620152014
Revenue $B0.00.00.00.00.00.00.00.00.00.0◌◌
Operating income $B−0.2−0.2−0.2−0.1−0.1−0.1−0.1−0.0−0.0−0.0−0.0−0.0
EBITDA $B−0.2−0.2−0.2−0.1−0.1−0.1−0.1−0.0−0.0−0.0−0.0−0.0
Income tax $B−0.00.0−0.0−0.00.00.00.00.00.00.00.00.0
Net income $B−0.2−0.2−0.3−0.1−0.1−0.1−0.1−0.0−0.0−0.0−0.0−0.0
Free cash flow $B◌−0.2−0.1−0.1−0.1−0.1−0.1−0.0−0.0−0.0−0.0−0.0
EPS, diluted $◌◌13.76−24.86−25.02−1.52−2.45−2.13−1.80−2.22−19.21◌
Dividend / sh $◌◌◌◌◌◌◌◌◌◌◌◌
Payout % — not applicable: no dividend————————————
ROE %−25.2−59.3−289.2−124.9−58.8−80.9−122.7−75.3−48.1———
Shares out B0.080.060.040.070.050.050.030.020.020.010.00◌

Slide the table for earlier years. "—" not applicable · "◌" not available in our data.

More in this sector

Other companies filing in the same sector

Provenance

Company facts, as filed

How we verify · 1 failure in 43 reconciliationsAUDITED

Reconciled in 11 of the 12 fiscal years we could check. 16 checks were skipped: the balance sheet is not tagged before 2015. Eight checks were skipped: EPS is not tagged before 2015.

EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidityCurrency consistency1 failure
ActivityPharmaceutical Preparations
Listed onNASDAQ
Incorporated inDelaware
Fiscal year endsDecember 31
Data on record since2014

Share this section

Download image